Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Temsirolimus in Combination with Bendamustine and Rituximab (BeRT) for the Treatment of Relapsed Mantle Cell and Follicular Lymphoma: Final Phase I/II Results

Georg Hess, MD, Wagner Karola, Paul LaRosee, MD, Ulrich Keller, Johannes Atta, Mathias Witzens-Harig, MD, Anne Crombé, Christoph Medler, Peter Borchmann, MD, Ulrich Bitz, MD, Christian Lerchenmüller, MD, Matthias Theobald, MD, Martin H. Dreyling, MD PhD

Blood (2016) 128 (22): 2977.

https://doi.org/10.1182/blood.V128.22.2977.2977

Published: 2016

Journal Articles

Safety and Clinical Activity of Temsirolimus in Combination with Rituximab and DHAP in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma - Report of the Prospective, Multicenter Phase II STORM Trial

Mathias Witzens-Harig, MD, Andreas Viardot, Ulrich Keller, Christian Buske, Anne Crombé, Elisabeth Hoenig, Johannes Atta, Johann Schmier, MD, Julia Meissner, MD, Anthony D. Ho, MD, Paul LaRosee, MD, Reinhard Marks, MD, Martin Dreyling, MD PhD, Georg Hess, MD

Blood (2016) 128 (22): 3028.

https://doi.org/10.1182/blood.V128.22.3028.3028

Published: 2016

Journal Articles

Temsirolimus in Combination with Bendamustine and Rituximab for the Treatment of Relapsed Mantle Cell and Follicular Lymphoma: Report on an Ongoing Phase I/II Trial

Georg Hess, MD, Ulrich Keller, Johannes Atta, Ulrich Bitz, MD, Christian Lerchenmueller, Wagner Karola, Christoph Medler, Christian Ruckes, Mathias Witzens-Harig, MD, Kai Huebel, Paul LaRosee, Martin H. Dreyling, MD PhD

Blood (2015) 126 (23): 3930.

https://doi.org/10.1182/blood.V126.23.3930.3930

Published: 2015

Journal Articles

German Hodgkin Study Group Phase I Trial Of Doxorubicin, Vinblastine, Dacarbazine, and Lenalidomide (AVD-Rev) For Older Hodgkin Lymphoma Patients

Boris Böll, MD, Annette Plütschow, PhD, Michael Fuchs, MD, Dennis A. Eichenauer, MD, Indra Thielen, MD, Bastian von Tresckow, MD, Karolin Behringer, MD, Johannes Atta, Michael Pfreundschuh, Prof, MD, Michaela Feuring-Buske, MD, Martin Vogelhuber, MD, Martin Sökler, MD, Andreas Engert, MD, Peter Borchmann, MD

Blood (2013) 122 (21): 3054.

https://doi.org/10.1182/blood.V122.21.3054.3054

Published: 2013

Journal Articles

Elimination of Established Risk-Factors in Primary Central Nervous System Lymphoma - Impact of High-Dose Chemotherapy Followed by Autologous Stem-Cell Transplantaion - a Multicenter Retrospective Analysis

Elisabeth Schorb, MD, Benjamin Kasenda, MD, Johannes Atta, Nikolas von Bubnoff, MD, Thomas Elter, MD, Georg Hess, Stefan W. Krause, MD, Anke Morgner, Kaun Stephan, Kristina Fritsch, MD, Jürgen Finke, MD, Gerald Illerhaus

Blood (2011) 118 (21): 3089.

https://doi.org/10.1182/blood.V118.21.3089.3089

Published: 2011

Journal Articles

Temsirolimus in Combination with Bendamustine and Rituximab for the Treatment of Relapsed Mantle Cell and Follicular Lymphoma: Report on An Ongoing Phase I/II Trial

Georg Hess, MD, Ulrich Keller, MD, Johannes Atta, Christian Buske, Peter Borchmann, MD, Christoph Medler, Mathias Witzens-Harig, Martin H. Dreyling, PhD

Blood (2011) 118 (21): 2697.

https://doi.org/10.1182/blood.V118.21.2697.2697

Published: 2011

Journal Articles

Compound GW506U78 Has High Single-Drug Activity and Good Feasibility in Heavily Pretreated Relapsed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LBL) and Offers the Option for Cure with Stem Cell Transplantation (SCT).

Nicola Goekbuget, MD, Renate Arnold, MD, Johannes Atta, MD, Patrick Brück, MD, Stella Hermann, MD, Heinz Horst, MD, Mustafa Kondakci, MD, Roswitha Kotthoff, Oliver Ottmann, MD, Thorsten Raff, MD, Richard Ratei, MD, Mathias Schmid, MD, Michael Stadler, MD, Dieter Hoelzer, MD, PhD

Blood (2005) 106 (11): 150.

https://doi.org/10.1182/blood.V106.11.150.150

Published: 2005

Journal Articles

Early prediction of response in patients with relapsed or refractory Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph + ALL) treated with imatinib

Barbara Wassmann, Heike Pfeifer, Urban J. Scheuring, Anja Binckebanck, Nicola Gökbuget, Johannes Atta, Patrick Brück, Harald Rieder, Claudia Schoch, Lothar Leimer, Rainer Schwerdtfeger, Gerhard Ehninger, Thomas Lipp, Jolanta Perz, Matthias Stelljes, Harald Gschaidmeier, Dieter Hoelzer, Oliver G. Ottmann

Blood (2004) 103 (4): 1495–1498.

https://doi.org/10.1182/blood-2003-01-0154

Published: 2004

Journal Articles

Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl–positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571)

Urban J. Scheuring, Heike Pfeifer, Barbara Wassmann, Patrick Brück, Johannes Atta, Eduard K. Petershofen, Brigitte Gehrke, Harald Gschaidmeier, Dieter Hoelzer, Oliver G. Ottmann

Blood (2003) 101 (1): 85–90.

https://doi.org/10.1182/blood-2002-02-0360

Published: 2003

NARROW

Temsirolimus in Combination with Bendamustine and Rituximab (BeRT) for the Treatment of Relapsed Mantle Cell and Follicular Lymphoma: Final Phase I/II Results

Safety and Clinical Activity of Temsirolimus in Combination with Rituximab and DHAP in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma - Report of the Prospective, Multicenter Phase II STORM Trial

Temsirolimus in Combination with Bendamustine and Rituximab for the Treatment of Relapsed Mantle Cell and Follicular Lymphoma: Report on an Ongoing Phase I/II Trial

German Hodgkin Study Group Phase I Trial Of Doxorubicin, Vinblastine, Dacarbazine, and Lenalidomide (AVD-Rev) For Older Hodgkin Lymphoma Patients

Elimination of Established Risk-Factors in Primary Central Nervous System Lymphoma - Impact of High-Dose Chemotherapy Followed by Autologous Stem-Cell Transplantaion - a Multicenter Retrospective Analysis

Temsirolimus in Combination with Bendamustine and Rituximab for the Treatment of Relapsed Mantle Cell and Follicular Lymphoma: Report on An Ongoing Phase I/II Trial

Compound GW506U78 Has High Single-Drug Activity and Good Feasibility in Heavily Pretreated Relapsed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LBL) and Offers the Option for Cure with Stem Cell Transplantation (SCT).

Early prediction of response in patients with relapsed or refractory Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph + ALL) treated with imatinib

Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl–positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only